News | July 29, 2021
RPG Life Sciences Q1FY22 PAT surges to Rs. 13.58 Cr
The company posted net profit of Rs.9.06 crores for the period ended June 30, 2020.
The company posted net profit of Rs.9.06 crores for the period ended June 30, 2020.
The Cephalosporin Injectables plant has a total capacity of 26.4 million vials per year while Ethiopia is having a demand for 16 million vials
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
The company had announced the expected date of completion of sale and disposal of the said undertaking is 90 days from the date of signing the Definitive Agreements.
SteriScience will infuse an additional amount of Rs. 74.5 crore, making a total investment commitment of Rs. 114.5 crore in BSL
The company has already embarked upon significant expansion in Turkey
Sitagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Subscribe To Our Newsletter & Stay Updated
